Related Experiment Video
Updated: Mar 19, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Discovery of potent macrocyclic HCV NS5A inhibitors
Wensheng Yu1, Bancha Vibulbhan1, Stuart B Rosenblum1
1Department of Medicinal Chemistry, Merck Research Laboratories, 126 E. Lincoln Avenue, Rahway, NJ 07065, USA.
Abstract:
HCV NS5A inhibitors have demonstrated impressive in vitro virologic profiles in HCV replicon assays and robust HCV RNA titer reduction in the clinic making them attractive components for inclusion in an all oral fixed-dose combination (FDC) regimen for the treatment of HCV infection. Merck's effort in this area identified MK-4882 and MK-8325 as early development leads. Herein, we describe the discovery of potent macrocyclic NS5A inhibitors bearing the MK-8325 or MK-4882 core structure.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Retrovirus Life Cycles
Subviral Agents
Inhibitors of Bacterial DNA Synthesis
Retroviruses

